Labcorp Holdings Inc. (LH)

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Ticker
LH
Exchange
NYSE
Sector
Healthcare
Industry
Diagnostics & Research
Market cap
$29.90B
52-week range
$245.00 - $375.10

Valuation

Share price
$370.75 (close of Nov 18, 2026)
P/E (TTM)
29.99x
Price to book
3.38x
Price to free cash flow
23.23x
Enterprise value
$36.42B
Book value per share
$108.96

Price performance

PeriodChange
1 day+0.68%
5 days-0.40%
1 month+16.61%
3 months+15.08%
6 months+45.07%
Year to date+47.78%
1 year+42.70%
3 years+75.10%
5 years+50.11%
10 years+242.50%
All time+1,401.06%

Short interest

As of
Oct 30, 2026
Short % of float
3.15%
Shares short
2.54M
Days to cover
3.01
Change since prior report
-0.52%
Source
FINRA consolidated short interest

Members of Congress who disclosed LH trades

April McClain Delaney · Robert Bresnahan · Alan Armstrong · Gilbert Ray Cisneros

Super investors holding LH

John Rogers (Ariel Investments LLC) · Ken Griffin (Citadel) · Wallace Weitz (Weitz Investment Management) · Mairs & Power (Mairs & Power Inc) · Ray Dalio (Bridgewater Associates)

Profitability and growth

Return on equity
10.17%
Return on invested capital
7.63%
Return on assets
4.77%
Return on capital employed
8.89%
Gross margin
28.76%
Net margin
6.28%
EBITDA margin
14.81%
Revenue growth
7.25%
Net income growth
17.49%
Free cash flow growth
10.05%

Cash flow and balance sheet

Free cash flow yield (TTM)
4.30%
Current ratio
1.41x
Net debt to EBITDA
3.01x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$13.95B
Cost of revenue
$9.94B
Gross profit
$4.01B
EBITDA
$2.07B
Net income
$876.50M
Earnings per share
$10.54
Interest expense
$224.10M
Shares outstanding
83.20M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$13.95B$4.01B$876.50M$10.54
2024-12-31$13.01B$3.62B$746.00M$8.89
2023-12-31$12.16B$3.36B$418.00M$4.80
2022-12-31$11.86B$3.71B$1.28B$14.05
2021-12-31$13.14B$4.99B$2.38B$24.60
2020-12-31$13.98B$4.95B$1.56B$15.99
2019-12-31$11.55B$3.25B$823.80M$8.42
2018-12-31$11.33B$3.18B$883.70M$8.71
2017-12-31$10.31B$3.09B$1.23B$11.99
2016-12-31$9.55B$2.85B$711.80M$6.94

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3128.76%6.28%10.17%7.63%
2024-12-3127.86%5.73%9.26%5.71%
2023-12-3127.67%3.44%5.31%3.88%
2022-12-3131.26%10.78%12.67%7.36%
2021-12-3138.01%18.10%23.14%14.19%
2020-12-3135.43%11.13%16.49%11.01%
2019-12-3128.15%7.13%10.78%7.12%
2018-12-3128.03%7.80%12.54%7.18%
2017-12-3129.99%11.90%18.03%9.62%
2016-12-3129.88%7.45%12.90%8.00%

Cash and debt by year

Period endCashDebt
2025-12-31$532.30M$5.08B
2024-12-31$1.52B$5.33B
2023-12-31$536.80M$4.05B
2022-12-31$320.60M$5.04B
2021-12-31$1.47B$5.42B
2020-12-31$1.32B$5.42B
2019-12-31$337.50M$5.79B
2018-12-31$426.80M$5.99B
2017-12-31$316.60M$6.34B
2016-12-31$433.60M$5.30B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$1.21B$125.80M
2024-12-31$1.10B$116.70M
2023-12-31$874.10M$128.70M
2022-12-31$1.53B$116.80M
2021-12-31$2.69B$132.90M
2020-12-31$1.75B$111.70M
2019-12-31$1.04B$107.00M
2018-12-31$925.60M$91.60M
2017-12-31$1.19B$109.70M
2016-12-31$918.20M$109.60M

Dividend history

Most recent payment
Aug 28, 2026
Paid in the last twelve months
$2.88
Payment dateDividend per share
2026-08-28$0.72
2026-05-29$0.72
2026-02-27$0.72
2025-11-26$0.72
2025-08-28$0.72
2025-05-29$0.72
2025-02-27$0.72
2024-11-26$0.72

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-28Sep 2026$4.65
2026-07-30Jun 2026$4.79
2026-04-30Mar 2026$4.09
2026-02-17Dec 2025$3.95
2025-10-28Sep 2025$4.13
2025-07-24Jun 2025$4.14
2025-04-29Mar 2025$3.73
2025-02-06Dec 2024$3.40

Filings and sources

Company website
labcorp.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Medpace Holdings, Inc. (MEDP) · Quest Diagnostics Inc (DGX) · Revvity, Inc. (RVTY) · Mettler-Toledo International Inc (MTD) · Charles River Laboratories International, Inc. (CRL) · Illumina, Inc. (ILMN) · ICON plc (ICLR) · Waters Corp (WAT)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades